Replimune Group Stock (NASDAQ:REPL), Quotes and News Summary benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
31.07.2023 - Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a . Seite 1
Incyte (INCY) and Replimune (REPL) Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Emerald Advisers LLC cut its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 18.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 963,041 shares of the company’s stock after selling 223,000 shares during the period. Emerald Advisers LLC […]